metaPreg - Ethosuximide (Epilepsy) during pregnancy

Ethosuximide (Epilepsy)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.82 [0.94, 8.45]	0%	7 studies	140	46	not evaluable	ROB	-
Major congenital malformations	3.13 [0.99, 9.93]	0%	7 studies	134	46	not evaluable	ROB	-
Congenital heart defects	4.26 [0.38, 47.27]	0%	2 studies	9	12	not evaluable	ROB	-
Hypospadias	4.12 [0.37, 45.30]	0%	2 studies	9	12	not evaluable	ROB	-
Neural Tube Defects	18.80 [1.26, 279.89]	0%	2 studies	2	12	not evaluable	ROB	37.09 [1.84; .]
Digestive system anomalies	7.99 [0.39, 163.81]	-	1 study	3	12	not evaluable	ROB	-
Eye defects	5.33 [0.29, 97.49]	-	1 study	7	2	not evaluable	ROB	-
Limb defects	11.21 [0.51, 246.80]	-	1 study	2	12	not evaluable	ROB	-
Minor congenital malformations	2.20 [0.19, 25.52]	-	1 study	6	4	not evaluable	ROB	-
Oro-facial clefts	18.71 [0.72, 484.16]	-	1 study	1	12	not evaluable	ROB	-
Polydactyly	6.33 [0.09, 458.24]	-	1 study	2		not evaluable	ROB	-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation	-	-	0 study					-
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neuro-developmental disorders (as a whole)	8.50 [0.44, 163.89]	-	1 study	5	2	not evaluable	ROB	-
Hide endpoints reported in only one study ...